ImpediMed Limited (ASX:IPD)

Market Cap	21.97M -78.4%
Revenue (ttm)	14.61M +14.8%
Net Income	-24.91M
EPS	-0.01
Shares Out	3.66B
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	7,143,844
Open	0.0060
Previous Close	0.0060
Day's Range	0.0050 - 0.0060
52-Week Range	0.0030 - 0.0520
Beta	1.07
Analysts	Buy
Price Target	0.02 (+233.33%)
Est. Earnings	Oct 27, 2026

About ImpediMed

ImpediMed Limited, a medical technology company, engages in the development, manufacture, and sale of bioimpedance spectroscopy (BIS) systems and software services in Australia, Europe, North America, and internationally. The company offers SOZO Digital Health Platform which transforms fluid status and tissue composition into insights with a single scan; L-Dex Analysis for Lymphedema, designed for early lymphedema detection; BodyComp Analysis; Segmental BodyComp Analysis; and HF-Dex Analysis for Heart Failure. It also provides Lymphedema Preven...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1999
• Employees: 66
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: IPD

Financial Performance

In fiscal year 2026, ImpediMed's revenue was 14.61 million, an increase of 14.85% compared to the previous year's 12.72 million. Losses were -24.91 million, 7.19% more than in 2025.

Analyst Summary

According to 4 analysts, the average rating for IPD stock is "Buy." The 12-month stock price target is $0.02, which is an increase of 233.33% from the latest price.

Price Target

$0.02

(233.33% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 7, 2026

Data Sources Report a data error